The review study suggests a possible dosage link of GLP-1 with onset of NAION. Wegovy and Ozempic are identical GLP-1 blockers with the only thing being different is dosage strength. While both have demonstrated cases of NAION, the higher dose Wegovy has shown more relative cases.